About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/24/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/24/2021.

Sharing Decision-making Program for HCC Patients Treatment Decisions

Clinicaltrials.gov identifier NCT03926039

Recruitment Status Recruiting

First Posted April 24, 2019

Last update posted February 26, 2020

Study Description

Brief summary:

Aim: Explore the effectiveness of sharing decision-making program interventions in the early stage of HCC to reduce treatment decisions conflicts and improving decision-making satisfaction. Design: An experimental design will be used in the study. The 102 primary liver cancer patients, who were diagnosed with Barcelona stage(BCLC stage) 0-A, will be recruited and randomized to the control or intervention group. The intervention measures in this study "sharing decision-making plan" mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process.

  • Condition or Disease:Hepatocellular Cancer
  • Intervention/Treatment: Behavioral: sharing decision-making program
  • Phase: N/A
Detailed Description

The effectiveness of sharing decision-making program interventions in the early stage of HCC to reduce treatment decisions conflicts and improving decision-making satisfactionHepatocarcinoma (HCC) is a high incidence and high mortality disease. Hepatocarcinoma is also a very common disease in Taiwan. Treatment options are limited to those patients with advanced Hepatocarcinoma. However, there are many options for patients with compensated cirrhosis, and small liver tumors are potentially resectable. When patients understood the detailed assessment of the disease both doctors and patients can set the best treatment goals. Sharing decision-making is a patient-centered collaborative processes that enable individuals and their healthcare providers to make decisions together, but patient engagement appears to be less optimistic and there is a lack of evidence that the link between sharing decision-making measures and patient behavior and health outcomes. When decisions are made under social stress or time constraints, people may make less than optimal decisions when they lack sufficient information or skills. Since then the treatment does not match the expected results, often result in decision regrets or arguments with the medical team, and even evolved into medical lawsuits. Therefore, the purpose of this study is to explore the effectiveness of sharing decision-making program interventions in the early stage of HCC to reduce treatment decisions conflicts and improving decision-making satisfaction. In this study, investigators took the experimental design to assess the cases of early hepatocellular carcinoma in hepato- gastroenterology, surgery and oncology clinical in a teaching hospital in the eastern part of Taiwan. The intervention measures in this study "sharing decision-making plan" mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process. According to Elwyn et.al. (2012), the decision-sharing model was proposed to intervene in the treatment decision-making of early liver cancer patients, including Choice talk, Option talk, Decision talk, and decision-making. Decision support for the process, where the investigator meets with the patient and its important others in the interdisciplinary discussion room or ward meeting room. Second, decision assistance tools. Decision assistance tools provide information about options and outcomes, and clarify personal values to help people participate in decision making. The aim is to supplement, rather than replace, medical staff counseling (Collins et al., 2009), and the quality of decision aids is very important. Satisfaction with the use of tools is associated with increased patient satisfaction and reduced decision-making. Patients can benefit from computerized decision-making tools without the need to increase physician involvement. The research tools include basic population data, clinical stage of disease, self-efficacy scale of hepatocellular carcinoma, Decision Decision Confidence Scale (DCS), decision self-efficacy scale , Decision Satisfaction Scale and Chinese Simplified-form Mandarin Health Literacy Scale. The obtained data were collected and analyzed by SPSS20.0 for Window software. The main statistical methods include descriptive statistics, T-test, analysis of variance, Pearson Product Moment correlation coefficient and Generalized Estimating Equations (GEEs) ).

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 102 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Blocked Randomization is a common disease in patients with liver cancer. In order to avoid excessive concentration of the patient control group and the experimental group, the mining blocks are randomly assigned.
  • Masking: Single (Participant)
  • Primary Purpose: Other
  • Official Title: The Effectiveness of Sharing Decision-making Program Interventions in the Early Stage of HCC to Reduce Treatment Decisions Conflicts and Improving Decision-making Satisfaction
  • Actual Study Start Date: February 2019
  • Estimated Primary Completion Date: October 2020
  • Estimated Study Completion Date: October 2020
Arms and interventions
Arm Intervention/treatment
Experimental: sharing decision-making program interventions
Description of conventional traditional treatment options and add sharing decision-making program The intervention measures in this study "sharing decision-making plan" mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process.
Behavioral: sharing decision-making program
Sharing decision-making talks and decision-making assistance tools used in the process
Outcome Measures
  • Primary Outcome Measures: 1. Liver Cancer Treatment Options Related Knowledge Scale [ Time Frame: 1 week ]
    A total of 20 questions total score of 100 points, the higher the knowledge, the better.Total scale range was 5-100 points.
  • 2. control preference scale [ Time Frame: 1 week ]
    Nominal variable, 1 point is make a decision by participant ,2 point is Seriously consider the doctor's opinion, and then make the decision about the treatment participant, and 3 point is the individual will make a decision together with the doctor. 4 point is My doctor will make the final decision on the treatment and must seriously consider my opinion and 5 point make a decision by the doctor.
  • 3. Decisional Conflict Scale [ Time Frame: 1 week ]
    5 questions for a total of 16 questions, respectively, to assess the uncertainty of the subscale (10-12 questions) the subscale total score range 0-300 points , informed subscales (1-3 questions) the subscale total score range 0-300 points, values subscales (4-6 questions) the subscale total score range 0-300 points, support subscales ( 7-9 questions) the subscale total score range 0-300 points, effective decision-making scale (13-16 questions) the subscale total score range 0-300 points,Each question is scored on a Likert scale of 0-4 points (very strongly agreed to very disagree), then multiplied by 25 so that each question may score 0-100 points. A score of 0 is a good decision, and a score of 100 is the worst decision. total score were 0 to 1600 points.
  • 4. Decision self-efficacy scale [ Time Frame: 1 week ]
    The scale included 11 questions, and participants were asked to think about how confident they were in making informed choices in 11 situations. The scoring for each situation is scored on a Likert scale with 0-4 points (very agrees to very disagree) for each question, then multiplied by 25 so that each question may score 0-100 points. The higher the score, the more confident participant are. Each question 0 points is not confident, 100 points is very confident. total score range is 0- 1100 points
  • 5. Satisfaction with Decision Instrument [ Time Frame: 1 week ]
    The content consists of 6 items, with a score of 1-5 points (very strongly disagreed and very agreeable) for each question. The score may be 6-30 points. The higher the score, the higher the satisfaction with the decision. A score of 6 indicates that the extreme dissatisfaction of 30 points indicates extreme satisfaction.
  • 6. Decision Regret Scale [ Time Frame: 3 months later ]
    There are 5 questions in the content of the scale. The scoring of each situation is scored on the Likert scale with 0-4 points (very agree and very disagree) for each question. The first question, the third question and the fifth question are The forward question, in which the second and fourth questions are reverse questions, need to be scored in reverse, then multiplied by 25, so that each question may score 0-100 points. The higher the score, the more regret it is. Total score is 0-500 points.
Eligibility Criteria
  • Ages Eligible for Study: 20 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. Primary liver cancer patients (ICD 10 is C22.0) and Barcelona stage (BCLC stage) 0-A.

2. At least 20 years of age.

3. No mental illness.

4. Patients who can communicate in Mandarin or Taiwanese.

Exclusion Criteria:

1. Don't know himself condition.

2. Unconscious patients.

3. Patients with liver cancer resection or partial liver resection were performed within
3 months.

Contacts and Locations
Contacts

Contact: Tsae Jyy Wang, PhD +8869112461360 tsaejyy@mtumhs.edu.tw

Contact: Yueh-Ling Liao, master +8860972200072 q868069@gmail.com

Locations

Taiwan
Lo-Hsu medical foundation Lotung Poh-Ai hospital
Yilan

Sponsors and Collaborators

National Taipei University of Nursing and Health Sciences

Lotung Poh-Ai Hospital

Investigators

Principal Investigator: Tsae Jyy Wang, PhD National Taipei University of Nursing and Health Sciences

More Information